Extraordinary General Meeting 2025

The full text of the call can be found in press releases and as an attachment on this page.

The shareholders of Sprint Bioscience AB (publ), reg. no. 556789-7557, (the "Company") are hereby invited to an Extraordinary General Meeting on April 2, 2025 at 15.00 at Sprint Bioscience's premises at Novum, Hälsovägen 7, 141 57 Huddinge. Voting registration starts at 14.30.

Right to participate
The right to participate in the Extraordinary General Meeting belongs to those who are registered as shareholders in the share register maintained by Euroclear Sweden AB on March 25, 2025, and who notify their intention to participate no later than March 27, 2025. Notification shall be made in writing by e-mail to sprintbioscience@fredersen.se or by mail to Sprint Bioscience c/o Fredersen Advokatbyrå, Birger Jarlsgatan 8, 114 34 Stockholm. The notification must state the name, address, personal or corporate identity number, telephone number and, where applicable, the number of advisors (maximum two).

Nominee-registered shares
Shareholders whose shares are registered in the name of a nominee, i.e. held in a custody account by a bank or securities institution, must register their shares in their own name in order to be included as a shareholder in the production of the share register. Such registration, which may be temporary, must be completed by May 2, 2024, which means that the shareholder must instruct the nominee well before that date.

Ombudsmen
If a shareholder intends to be represented at the meeting by a proxy, a power of attorney must be issued for the proxy. The power of attorney must be in writing, dated and signed by the shareholder. If the shareholder is a legal entity, a copy of the registration certificate or equivalent authorization document must be attached to the notification. The original power of attorney, registration certificate and other authorization documents should be sent to the Company at the above address well in advance of the meeting. If the power of attorney and other authorization documents have not been submitted in advance, they must be presented at the meeting. Proxy forms are available at the Company and at www.sprintbioscience.com and sent on request to shareholders who provide their postal address.